Sirolimus for antiphospholipid syndrome
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests whether sirolimus (an immune-calming drug) is safe and helpful for people with antiphospholipid syndrome (APS), a condition that raises the risk of blood clots. If you join, you'll get either sirolimus or a placebo alongside your usual treatment, to see if it reduces clotting problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have been diagnosed with antiphospholipid syndrome (APS)
- You are already on a stable combination of medications for APS
- You are not pregnant, planning pregnancy, or breastfeeding
- You have not had a major surgery within the last month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if sirolimus, a medicine that calms the immune system, can safely raise platelet counts in people with antiphospholipid antibodies and persistently low platelets. It may be an option if other treatments haven't worked or you want a simpler drug plan.
This trial tests whether sirolimus, a medication usually used to prevent organ transplant rejection, can help reduce lupus disease activity. If you have active lupus that isn't severe in your kidneys or brain, this could be a new treatment option.
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
This Phase 2 trial studies whether sirolimus can slow or prevent functional decline (more difficulty with daily activities) in older adults. You may be considered if you’re in the right age range and have no major heart, lung, liver, kidney, or recent bleeding/clotting problems.
This early-phase study tests daratumumab, an immune-targeting drug, for people with primary antiphospholipid syndrome (APS). It aims to see whether it can reduce APS activity and improve outcomes while you continue your usual blood-thinning treatment.
This study tests if belimumab lowers harmful antibody levels in people with antiphospholipid syndrome (APS), a condition that increases blood clot risk. It may help those who are already on a stable APS treatment plan.
Hear when a new Primary Antiphospholipid Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.